Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Cat Gr:Policy Res. for Health Sys. Transf.- Canadian Healthcare Workforce

University of Toronto

$149,953.00

An international comparative policy analysis of pharmacist-administered long-acting injectable buprenorphine

EF 2022-23

Résumé
Opioid addiction is a condition where individuals continue to use opioids even with negative consequences. People who use opioids are at higher risk of infection, overdose, and death. Some of the most effective treatments for opioid addiction are the medications methadone or buprenorphine, which reduce the risk of drug-related deaths. However, there are still many difficulties with these treatments; they often require patients to go daily to a clinic or pharmacy to get their medication or be watched by a pharmacist while they take their medication. This makes it hard to get the right care, can make it more expensive, can lead to stigma, and makes it less likely that people will continue with treatment. A strategy to overcome this is a new type of buprenorphine medication; each dose is injected into the patient and lasts a week or a month. It is available in countries such as Canada and Australia, and in some of their provinces and states, a patient's pharmacist can do the injections instead of a doctor or nurse, which can make it easier to get treatment. Recently, pharmacists have been providing more services through pharmacies (like flu and COVID vaccines), so they are well-placed to provide buprenorphine injections. For provinces that are looking to also use pharmacists to inject buprenorphine, policymakers need to learn how other areas are doing this, whether there were any specific factors that led to these policies, and any barriers or negative effects. By looking at policy documents and talking to policymakers, our research will compare these policies across six provinces and states in Canada and Australia. This will include what training pharmacists need, how the injections will be regulated, and how pharmacists will be paid for this service. Throughout the project, we will work with policymakers and other stakeholders, including people who use opioids, to make sure the research is focused on improving the experiences and health of people who use opioids.
Programme
Cat Gr:Policy Res. for Health Sys. Transf.- Canadian Healthcare Workforce
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
475149
Name
Sud Abhimanyu
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Policy Research for Health System Transformation
Projecttitle
An international comparative policy analysis of pharmacist-administered long-acting injectable buprenorphine
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$149,953
Cihrequipment2
$0
Programname2
Cat Gr:Policy Res. for Health Sys. Transf.- Canadian Healthcare Workforce
Keyworddelim
Buprenorphine; Comparative Policy Analysis; Health Policy; Health Systems; Opioid Agonist Therapy; Opioid Use Disorder; Pharmacy Practice; Scope Of Practice
Abstract
Opioid addiction is a condition where individuals continue to use opioids even with negative consequences. People who use opioids are at higher risk of infection, overdose, and death. Some of the most effective treatments for opioid addiction are the medications methadone or buprenorphine, which reduce the risk of drug-related deaths. However, there are still many difficulties with these treatments; they often require patients to go daily to a clinic or pharmacy to get their medication or be watched by a pharmacist while they take their medication. This makes it hard to get the right care, can make it more expensive, can lead to stigma, and makes it less likely that people will continue with treatment. A strategy to overcome this is a new type of buprenorphine medication; each dose is injected into the patient and lasts a week or a month. It is available in countries such as Canada and Australia, and in some of their provinces and states, a patient's pharmacist can do the injections instead of a doctor or nurse, which can make it easier to get treatment. Recently, pharmacists have been providing more services through pharmacies (like flu and COVID vaccines), so they are well-placed to provide buprenorphine injections. For provinces that are looking to also use pharmacists to inject buprenorphine, policymakers need to learn how other areas are doing this, whether there were any specific factors that led to these policies, and any barriers or negative effects. By looking at policy documents and talking to policymakers, our research will compare these policies across six provinces and states in Canada and Australia. This will include what training pharmacists need, how the injections will be regulated, and how pharmacists will be paid for this service. Throughout the project, we will work with policymakers and other stakeholders, including people who use opioids, to make sure the research is focused on improving the experiences and health of people who use opioids.
Competitiondate
202210
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sud, Abhimanyu; Hickcox, Samuel E
Approvedterm
1 an 0 mois
Cihrcontribution2
Patient Oriented Research~ $149,953~ $0~